Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsing Multiple Sclerosis (RMS): later-stage trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Relapsing Multiple Sclerosis (RMS): 4 US clinical trials tracked, none currently recruiting.
Relapsing Multiple Sclerosis (RMS) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 4 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is TG Therapeutics, running 3 of these trials.
Enrollment posture brief
Registry condition relapsing-multiple-sclerosis-rms
OPEN 0 | RECR 0% | LATE 4 | EARLY 0 | RANK #4115 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Relapsing Multiple Sclerosis (RMS) has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsing Multiple Sclerosis (RMS) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsing Multiple Sclerosis (RMS) is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
TG Therapeutics
NCT04130997
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Novartis Pharmaceuticals
NCT06869785
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
TG Therapeutics
NCT03277261
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
TG Therapeutics
NCT03277248
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsing Multiple Sclerosis (RMS) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsing Multiple Sclerosis (RMS) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsing Multiple Sclerosis (RMS) page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Relapsing Multiple Sclerosis (RMS) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- TG Therapeutics sponsors the most Relapsing Multiple Sclerosis (RMS) trials on record, review their full trial history before evaluating a specific study. See TG Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsing Multiple Sclerosis (RMS) condition card totals 4 registered trials; most-linked intervention Ublituximab; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.